The large-capitalization S&P 500 index generated a total return of 28.7% in 2021, while the Russell 2000 small-cap index total return was just 14.8%. Bank of America analyst Jill Carey Hall says small-cap stocks became about 9% more attractive relative to large-cap stocks from a valuation perspective last year, and small-cap stocks are now cheap relative to large-cap stocks “across every metric…
“Some of the market’s most rewarding opportunities can be found in small-cap stocks,” declares the author of today’s article – and with that, he proceeds to highlight three of the most popular small-cap stocks right now among Robinhood investors. For these three stocks – which include a veterinary health company with a medical device that could help it tap into…
While large-cap stocks receive more attention from analysts and more investment, the author of today’s article reminds the reader that “small caps, over time, outperform their larger peers.” With that, she proceeds to highlight three small-cap stocks that are showing strong technical performance – including, in the biotech arena, a genetic-testing specialist. For more, CLICK HERE.
“We stick to our view that 2021 will be a stockpicker’s paradise with big money-making opportunities if you are willing to go against the grain,” asserts one small/mid-cap stock strategist cited in today’s article, which proceeds to highlight two penny stocks that boast “Strong Buy” consensus ratings and upside potential over 200%. For these two penny stocks, CLICK HERE.
Small and midcap stocks – or “smidcaps” – have had a strong November, and the author of today’s article asserts that this strong performance will continue: “This group has been beaten and battered for so long that many people simply doubt the move. But this is a big mistake. I don’t know about the next few days ahead, but smidcaps…
At the beginning of the year, the two biotechs highlighted in today’s article weren’t even big enough to be considered microcap stocks. Now, thanks to their respective COVID-19 vaccine programs, both are fast-growing small-cap stocks with “intriguing twists with their respective COVID-19 vaccine candidates.” So which of these two coronavirus stocks might be the better buy? CLICK HERE.
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.
Morgan Stanley’s chief US equity strategist believes that stocks hit their true bottom on March 23rd – and that the current rally could well lead to a true recovery. To prepare for the next bull run, he’s advising clients to buy into small-cap stocks, so today’s article highlights “three micro-cap penny stock companies with super-low entry costs (a dollar per…
Noting that we’re “beginning to see selectivity creep back into the marketplace following a period of indiscriminate buying”, the author of today’s article proceeds to identify the best sectors right now across large-cap, mid-cap and small-cap stocks, as well as a slew of “top scoring stocks” from those select sectors that may be the best buys for stock pickers right…
Today’s article outlines a mutual fund portfolio for aggressive retirement savers – i.e. investors who are still many years away from retirement (or who are closer to retirement but already have their in-retirement income needs covered). As the author notes, these individuals can “reasonably hold more in potentially more volatile subasset classes, such as small-cap stocks and foreign stocks and…